Savara Inc. (FRA:YB4P)

Germany flag Germany · Delayed Price · Currency is EUR
4.920
+0.240 (5.13%)
At close: Jan 7, 2026
67.35%
Market Cap1.21B
Revenue (ttm)n/a
Net Income (ttm)-98.56M
Shares Outn/a
EPS (ttm)-0.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume10
Open4.660
Previous Close4.680
Day's Range4.660 - 4.940
52-Week Range1.660 - 5.900
Betan/a
RSI49.22
Earnings DateMar 30, 2026

About Savara

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania. [Read more]

Industry Pharmaceutical Preparations
Founded 2007
Employees 59
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol YB4P
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.